The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score Is Associated With Poor Outcome of Acute Ischemic Stroke

Mengke Tian^{1,2}, Youfeng Li^{1,2}, Xiao Wang^{1,2}, Xuan Tian^{1,2}, Lu-Lu Pei^{1,2}, Xin Wang^{1,2}, Luyang Zhang^{1,2}, Wenxian Sun^{1,2}, Jun Wu^{1,2}, Shilei Sun^{1,2}, Mingming Ning^{3}, Ferdinando Buonanno^{3}, Yuming Xu^{1,2} and Bo Song^{1,2*}

^{1}Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ^{2}Henan Key Laboratory of Cerebrovascular Diseases, Zhengzhou, China, ^{3}Massachusetts General Hospital and Harvard Medical School, Clinical Proteomics Research Center and Cardio-Neurology, Boston, MA, United States

Background: The combined index of hemoglobin, albumin, lymphocyte, and platelet (HALP) is considered a novel score to reflect systemic inflammation and nutritional status. This study aimed to investigate the association between HALP score and poor outcome in patients with acute ischemic stroke (AIS).

Methods: Consecutive AIS patients within 24 h after onset were prospectively enrolled. Poor outcome was a combination of a new stroke event (ischemic and hemorrhagic) and all-cause death within 90 days and 1 year. The association between HALP score and poor outcome was analyzed using Cox proportional hazards.

Results: A total of 1,337 patients were included. Overall, 60 (4.5%) and 118 (8.8%) patients experienced poor outcome within 90 days and 1 year, respectively. Patients in the highest tertile of HALP score had a lower risk of poor outcome within 90 days and 1 year (hazard ratio: 0.25 and 0.42; 95% confidence intervals: 0.11–0.57 and 0.25–0.69, \(P\) for trend <0.01 for all) compared with those in the lowest tertile after adjusting relevant confounding factors. Adding HALP score to the conventional risk factors improved prediction of poor outcome in patients with AIS within 90 days and 1 year (net reclassification index, 48.38 and 28.95%; integrated discrimination improvement, 1.51 and 1.51%; \(P < 0.05\) for all).

Conclusions: Increased HALP score was associated with a decreased risk of recurrent stroke and death within 90 days and 1 year after stroke onset, suggesting that HALP score may serve as a powerful indicator for AIS.

Keywords: acute ischemic stroke, cohort study, HALP score, outcome, risk factors

INTRODUCTION

Stroke is a leading cause of death and long-term disability worldwide, with ischemic stroke as the most common subtype (1). Exploring new predictors of stroke prognosis may help in early identification of high-risk patients with poor outcome and contribute to more effective secondary prevention. Inflammation, abnormal blood coagulation, and poor nutritional status...
are associated with poor prognosis of acute ischemic stroke (AIS) (2–4). Lymphocytes have key regulatory functions in post-stroke inflammation (5). Platelet hyperactivity increases the risk of thromboembolism and atherosclerotic lesions and may lead to abnormal thrombosis, which exacerbates inflammation response (6). Anemia and hypoalbuminemia are manifestations of poor nutritional status and have been identified as risk factors for cerebrovascular events that may lead to poor prognosis in patients with AIS (7, 8). In this study, we explored the association between the combination of these four common indicators and the prognosis of AIS.

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is considered to be an easily calculated marker of systemic inflammation and nutritional status (9, 10) and has been found as a significant prognostic factor in patients with multiple tumors (11–13). However, it is unknown whether HALP score is associated with the poor outcome of AIS. Therefore, our study aimed to investigate the predictive value of HALP score in a prospective cohort of patients with AIS.

METHODS

Study Design and Population
The study was a prospective consecutive hospital-based cohort study. We enrolled patients with AIS within 24 h of onset from the Ischemic Cerebrovascular Disease Database of the First Affiliated Hospital of Zhengzhou University from January 2015 to June 2018, which has been published previously (14, 15). The diagnosis of AIS was based on the criteria of the World Health Organization (WHO) (16). The database was approved by the Ethics Committee, and informed consent forms were obtained from all patients or their relatives.

The exclusion criteria were as follows: (i) patients with active or chronic inflammatory disease; (ii) neoplastic hematologic disorders or using immunosuppressant drugs; (iii) major trauma or surgery within 3 months; (iv) patients without blood cell count data; and (v) severe liver and kidney dysfunction.

Clinical Assessment
Baseline clinical information was obtained from case report forms at admission, including demographic characteristics, medical histories, imaging features, and medication use. Clinical factors, including baseline stroke severity, the use of intravenous thrombolysis therapy, and stroke subtype, were also evaluated. The severity of AIS was assessed according to the National Institutes of Health Stroke Scale (NIHSS) at admission. Stroke subtypes were classified according to the Trial of Org 10172 in the Acute Stroke Treatment classification.

Laboratory Assay
Laboratory tests were obtained within 24 h of admission after stroke onset, including the serum albumin, hemoglobin, lymphocyte, and platelet levels. The blood counts were analyzed using an autoanalyzer (Beckman Coulter Hematology Analyzer LH750, USA). All the serum biochemical parameters were assayed using an automatic biochemical analyzer (Roche COBAS 8000 automatic biochemical analyzer). The HALP score was calculated according to the following formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (/L)/platelets (/L).

Outcome Assessments
The poor outcome was a combination of a new stroke event (ischemic and hemorrhagic) and all-cause death within 90 days and 1 year. Patients enrolled were followed up by face-to-face or telephone interviews at 90 days and 1 year after stroke onset.

Statistical Analyses
Continuous variables with normal distribution were expressed as mean ± standard deviation (SD), and skewed distribution were expressed as medians with interquartile ranges (IQRs). Categorical variables were expressed as frequencies (n) and percentages (%). Patients were classified into three groups based on the HALP score tertiles. Tests for linear trend of baseline characteristics across HALP score tertiles were performed using ANOVA for continuous variables and χ² trend analysis for categorical variables. The cumulative incidence risks of poor outcome across baseline HALP score were calculated with Kaplan–Meier curves and compared by log-rank test. Multivariate Cox proportional hazards models were used to assess the risk of poor outcome with HALP score tertiles. Unadjusted and adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated for the two higher HALP score groups (with the lowest group serving as a reference) and for a 1-SD increment of HALP score. Optimal HALP score cutoff values were obtained using receiver operating characteristic (ROC) curve analysis. C statistics, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate the incremental predictive ability of HALP score beyond the conventional model. Some conventional risk factors were selected as potential covariates for poor outcome of ischemic stroke based on prior knowledge. In addition, we used restricted cubic splines to evaluate the shape of the association between HALP score and outcomes with four knots defined at the fifth, 35, 65, and 95th percentiles of HALP score. Statistical analysis was performed using IBM SPSS software version 24.0 (SPSS, Inc., Chicago, IL, USA) and R (version 3.5.0). A two-tailed value of P < 0.05 was considered statistically significant.

RESULTS

Baseline Characteristics
A total of 1,337 patients were included in our analysis (Figure 1). The mean age of the patients was 60.55 years, and 30.5% of them were female. The study population was divided into three tertiles based on the HALP score value (Table 1). Compared with the higher HALP score patients, those with a lower HALP score were more likely to be older; be female; have atrial fibrillation; have lower lymphocyte, hemoglobin, and albumin levels; and have higher platelet counts, frequencies of cardioembolic stroke, and baseline NIHSS scores.
Figure 1 | Patient flowchart of the cohort.

Table 1 | Baseline characteristics of patients according to the HALP score tertiles.

| Variable | Overall | Tertile 1 (<36.65) | Tertile 2 (36.65–54.42) | Tertile 3 (>54.42) | P for trend |
|----------|---------|--------------------|-------------------------|--------------------|------------|
| Patients, n | 1,337 | 445 | 446 | 446 | – |
| Age, years, mean ± SD | 60.55 ± 12.45 | 63.20 ± 12.45 | 60.24 ± 11.92 | 58.20 ± 12.48 | <0.001 |
| Female, n (%) | 408 (30.5) | 179 (40.2) | 123 (27.6) | 106 (23.8) | <0.001 |
| Smoking, n (%) | 585 (43.8) | 198 (44.5) | 190 (42.6) | 197 (44.2) | 0.923 |
| Time from onset to blood sampling, h, median (IQR) | 17 (13-21) | 16 (11-21) | 17 (14-22) | 17 (14-22) | 0.345 |
| Medical history, n (%) | | | | | |
| Hypertension | 809 (60.5) | 274 (61.6) | 268 (60.1) | 267 (59.9) | 0.602 |
| Diabetes | 311 (23.3) | 97 (21.8) | 97 (21.7) | 117 (26.2) | 0.117 |
| Stroke history | 322 (24.1) | 114 (25.6) | 99 (22.2) | 109 (24.4) | 0.681 |
| Coronary heart disease | 159 (11.9) | 61 (13.7) | 48 (10.8) | 50 (11.2) | 0.250 |
| Atrial fibrillation | 125 (9.3) | 64 (14.4) | 36 (8.1) | 25 (5.6) | <0.001 |
| IV thrombolysis treatment, n (%) | 294 (22.0) | 114 (25.6) | 91 (20.4) | 89 (20.0) | 0.041 |
| Baseline NIHSS score, median (IQR) | 3 (2-6) | 4 (2-8) | 3 (2-6) | 3 (1-5) | <0.001 |
| Hemoglobin, g/l, median (IQR) | 138 (128–148) | 132 (120–143) | 138 (130–147) | 144 (134–153) | <0.001 |
| Albumin, g/l, median (IQR) | 40.9 (38.5–43.1) | 39.6 (37.4–42.1) | 40.9 (38.9–43.1) | 41.8 (39.6–44.1) | <0.001 |
| Lymphocyte, 10⁹/l, median (IQR) | 1.7 (1.3–2.2) | 1.2 (0.94–1.5) | 1.7 (1.4–2.0) | 2.2 (1.9–2.6) | <0.001 |
| Platelet, 10⁹/l, median (IQR) | 207 (173–250) | 234 (192–279) | 209 (176–247) | 186 (159–218) | <0.001 |
| Stroke etiology, n (%) | | | | | |
| Large artery atherosclerosis | 511 (38.2) | 164 (36.9) | 170 (38.1) | 177 (39.7) | 0.385 |
| Small artery disease | 329 (24.6) | 100 (22.5) | 119 (26.7) | 110 (24.7) | 0.448 |
| Cardioembolic stroke | 173 (13.0) | 80 (18.0) | 51 (11.4) | 43 (9.6) | <0.001 |
| Stroke of other determined etiology | 46 (3.4) | 18 (4.0) | 16 (3.6) | 12 (2.7) | 0.268 |
| Stroke of undetermined etiology | 277 (20.7) | 83 (18.7) | 90 (20.4) | 104 (23.3) | 0.086 |

HALP, hemoglobin, albumin, lymphocyte, and platelet; NIHSS, National Institutes of Health Stroke Scale.
Association Between HALP Score and Poor Outcome

After 90 days of follow-up, 60 (4.5%) patients were lost to follow-up and 60 (4.5%) patients experienced poor outcome. At the 1-year follow-up, 92 (6.9%) patients were lost and 118 (8.8%) patients experienced poor outcome (Figure 1). All Kaplan–Meier curves showed that patients in the lowest tertile of HALP score (<36.65) had the highest cumulative incidence of poor outcome within 90 days and at 1 year (log-rank \( P < 0.05 \) for all; Figure 2).

After adjustment for age, sex, history of hypertension, diabetes, ischemic stroke, coronary heart disease, atrial fibrillation, smoking, time from onset to blood sampling, IV thrombolysis treatment and baseline NIHSS score, higher levels of HALP score were associated with decreased risk of poor outcome within 90 days and 1 year (Table 2). The adjusted HRs (95% confidence intervals) for the highest vs. lowest tertile of HALP score were 0.25 (0.11–0.57) for poor outcome at 90 days and 0.42 (0.25–0.69) at 1 year. Similarly, on continuous analyses, each 1-SD increase of the HALP score was associated with 90-day and 1-year poor outcome (Table 2). ROC curve analysis of HALP score and poor outcome at 90-day and 1-year follow-up indicated that optimal cutoff values for HALP score were 33.82 and 32.77, respectively. The sensitivity and specificity were 53.3 and 75.9% (C statistic: 0.69, 95% CI: 0.66–0.71, \( P < 0.001 \)) for 90-day poor outcome, and for 1-year poor outcome, they were 49.2 and 74.3% (C statistic: 0.65, 95% CI: 0.62–0.67, \( P < 0.001 \)).

In addition, multivariable-adjusted spline regression models showed J-shaped associations between HALP score and the risk of poor outcome within 90 days and 1 year (Figure 3).

Incremental Predictive Ability of HALP Score

Adding HALP score to a multivariable model, which included age, sex, history of hypertension, diabetes, ischemic stroke, coronary heart disease, atrial fibrillation, smoking, intravenous (IV) thrombolysis treatment, and baseline NIHSS scores, significantly improved its predictive ability (Table 3). The continuous net reclassification improvement was 48.38% (\( P < 0.001 \)) and 28.95% (\( P = 0.002 \)) for 90-day and 1-year poor outcome, respectively. IDI was 1.51% (\( P = 0.027 \)) and 1.51% (\( P < 0.001 \)) for 90-day and 1-year poor outcome, respectively.

---

**TABLE 2 | HRs (95% CIs) for poor outcome according to HALP score tertiles.**

| HALP score | Poor outcome within 90 days | Poor outcome within 1 year |
|------------|-----------------------------|---------------------------|
|            | Events, \( n \) (%) | Unadjusted Model | Adjusted Model* | Events, \( n \) (%) | Unadjusted Model | Adjusted Model* |
| Tertile 1  | 35 (7.9) | Reference | Reference | 63 (14.2) | Reference | Reference |
| Tertile 2  | 18 (4.0) | 0.50 (0.29–0.89) | 0.61 (0.34–1.10) | 33 (7.4) | 0.51 (0.33–0.77) | 0.60 (0.39–0.92) |
| Tertile 3  | 7 (1.6) | 0.19 (0.09–0.44) | 0.25 (0.11–0.57) | 22 (4.9) | 0.33 (0.20–0.54) | 0.42 (0.25–0.69) |
| \( P \) for trend | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 |
| Per SD increment | 60 (4.5) | 0.96 (0.95–0.98) | 0.97 (0.96–0.99) | 118 (8.8) | 0.98 (0.97–0.99) | 0.98 (0.97–0.99) |

HR, hazard ratio; CI, confidence interval; SD, standard deviation; HALP, hemoglobin, albumin, lymphocyte, and platelet; NIHSS, National Institutes of Health Stroke Scale.

*Adjusted for age, sex, history of hypertension, diabetes, ischemic stroke, coronary heart disease and atrial fibrillation, smoking, time from onset to blood sampling, intravenous (IV) thrombolysis treatment, and baseline NIHSS scores.
FIGURE 3 | Association of hemoglobin, albumin, lymphocyte, and platelet (HALP) score with the risk of poor outcome among patients with acute ischemic stroke at 90-day and 1-year follow-up.

TABLE 3 | Reclassification and discrimination statistics for poor outcome by HALP score.

| Poor outcome within 90 days | C Statistic | NRI (Continuous), % | IDI, % |
|----------------------------|-------------|---------------------|--------|
| Model 1                    | 0.71 (0.69–0.74) | Reference          | Reference |
| Model 1 + HALP score       | 0.74 (0.72–0.77) | 0.146               | 48.38 (24.55–72.21) | <0.001 |
| Poor outcome within 1 year | Model 1     | 0.64 (0.62–0.67)   | Reference          | Reference          |
| Model 1 + HALP score       | 0.68 (0.65–0.71) | 0.070               | 28.95 (10.87–47.03) | <0.002 |

Model 1 adjusted for age, sex, history of hypertension, diabetes, ischemic stroke, coronary heart disease and atrial fibrillation, smoking, intravenous (IV) thrombolysis treatment, and baseline NIHSS scores. HALP; hemoglobin, albumin, lymphocyte, and platelet; CI, confidence interval; IDI, integrated discrimination improvement; NIHSS, National Institutes of Health Stroke Scale; NRI, net reclassification improvement.

DISCUSSION

We explored the prognostic value of the novel index HALP score in patients with AIS in this prospective cohort study and found that higher levels of HALP score at admission were highly associated with a decreased risk of recurrent stroke and death within 90 days and 1 year. Furthermore, we demonstrated that the addition of HALP score to the conventional risk factors could increase the discriminatory power and risk reclassification for recurrent stroke and death. These results suggested that decreased HALP score could be an independent risk factor of recurrent stroke and death.

Ischemic stroke initiates with gradual or sudden cerebral hypoperfusion, including oxidative stress, hemostatic activation, and inflammation, and eventually leads to a corresponding loss of neurological function (17). Ischemic brain tissue activates leukocytes and promotes their migration to the ischemic site by releasing pro-inflammatory chemokines (18). The inflammation triggers the process of thrombosis, in which platelets participate in adhesion, release reaction, and aggregation (6). Studies have shown that platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome (19). Lymphocytes play an important role in the elimination and repair of inflammation; lower lymphocyte counts were associated with increased infarct volume, neurological deterioration, and poor prognosis after ischemic stroke (20). Albumin has a neuroprotective effect because of its antagonism of oxidation, stagnant, thrombosis, and leukocyte adhesion (21, 22). Serum albumin levels can predict the prognosis of ischemic stroke (23). Hemoglobin has
oxygen-carrying capacity and can affect the energy balance in the penumbra (24). There is a U-shaped association between hemoglobin and poor prognosis of ischemic stroke (25). Studies have shown that a high hemoglobin concentration is associated with carotid atherosclerosis and may be a risk factor for ischemic stroke (26). Similarly, low hemoglobin and hematocrit levels are strongly associated with poor outcome and mortality after AIS (27). Further, serum albumin and hemoglobin concentrations have a predictive value for stroke recurrence and combined events (28, 29). The new indicator HALP score is based on the combination of the four hematological parameters mentioned above.

Recent studies have shown that the HALP score can reflect the inflammation–nutritional status of patients (9, 30) and has been proved to be an important prognostic indicator for patients with multiple tumors (10–12). Anemia and thrombosis could exacerbate inflammation, while lymphocytes reduce inflammation (26). Serum albumin has been considered an indicator of nutritional status. Some studies have also suggested that albumin reflects the severity of inflammation and illness in acute diseases (31). It is widely accepted that the inflammatory response and nutritional status are correlated with the prognosis of patients with stroke (4, 32, 33). HALP score is obtained by hemoglobin (g/L) × albumin (g/L) × lymphocytes (/L)/platelets (/L), which makes it a cost-effective, simple parameter to easily assess the inflammation–nutritional status. This finding may be significant because instant inflammation–nutritional status assessment can help clinicians assess prognosis and formulate appropriate treatment plans.

There were some limitations to this study. First, this was a single-center prospective study. Although we included patients in three branches, there was still a possibility of selection bias. Second, the potential influence of concomitant medications, such as thrombolytic therapy, oral anti-platelet, and statins, were not considered. Third, we only obtained the hemoglobin count, albumin levels, lymphocyte count, and platelet count at admission but did not present the dynamic change of HALP score at different stages. Therefore, multicenter cohort studies are still needed to validate the findings.

CONCLUSION
Our study indicated an association between HALP score and the risk of recurrent stroke and death within 90 days and 1 year, suggesting that HALP score at admission may act as a powerful indicator of recurrent stroke and death in patients with AIS.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
BS and YX designed the overall study with contributions from MN, FB, JW, and SS. MT designed and carried out experiments and collected data with YL, XiaW, XT, L-lP, XinW, LZ, and WS. MT wrote the manuscript. BS supervised this study, designed experiments, and edited the paper. All authors critically reviewed the manuscript and approved the submitted version.

FUNDING
This study was supported by the National Natural Science Foundation of China (81571158) and the Education Department of Henan Province (16A320054 and 172102310086).

ACKNOWLEDGMENTS
We thank the study participants and the clinical staff for their support and contribution to this study. This manuscript has been released as a preprint at Research Square (34).

REFERENCES
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. (2016) 133:e38-360. doi: 10.1161/CIR.0000000000000350
2. Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. (2016) 12:594–604. doi: 10.1038/nrneurol.2016.125
3. de Lau LM, Leebeek FW, de Maat MP, Koudstaal PJ, Dippel DW. A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke. Int J Stroke. (2010) 5:385–94. doi: 10.1111/j.1747-4949.2010.00468.x
4. Collaboration. FT. Poor nutritional status on admission predicts poor outcomes after stroke: observational data from the FOOD trial. Stroke. (2003) 34:1450–6. doi: 10.1161/01.STR.0000074037.49197.8C
5. Baird AE. The forgotten lymphocyte: immunity and stroke. Circulation. (2006) 113:2035–6. doi: 10.1161/CIRCULATIONAHA.105.620732
6. Reininger AJ, Bernlochner I, Penz SM, Ravanat C, Smethurst P, Farndale RW, et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol. (2010) 55:1147–58. doi: 10.1016/j.jacc.2009.11.051
7. Milionis H, Papavasileiou V, Eskandari A, D’Ambrogio-Remillard S, Ntaios G, Michel P. Anemia on admission predicts short- and long-term outcomes in patients with acute ischemic stroke. Int J Stroke. (2015) 10:224–30. doi: 10.1111/ijs.12397
8. Tanne D, Moldzhatzi N, Merzeliak O, Tisbari R, Toashi M, Schwammenthal Y. Anemia status, hemoglobin concentration and outcome after acute stroke: a cohort study. BMC Neurol. (2010) 10:22. doi: 10.1186/1471-2377-10-22
9. Xu SS, Li S, Xu HX, Li H, Wu CT, Wang WQ, et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. World J Gastroenterol. (2020) 26:828–38. doi: 10.3748/wjg.v26.i8.828
10. Shen X, Zhang YY, Wang W, Pan YY. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score in patients with small cell lung cancer before first-line treatment with etoposide and progression-free survival. Med Sci Monit. (2019) 25:5630–9. doi: 10.12659/MSM.917968
Prognostic Value of HALP Score

11. Cong L, Hu L. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma. *Int Immunopharmacol.* (2017) 46:75–9. doi: 10.1016/j.intimp.2017.02.027

12. Peng D, Zhang CJ, Gong YQ, Hao H, Guan B, Li XS, et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) score in patients with bladder cancer after radical cystectomy. *Sci Rep.* (2018) 8:794. doi: 10.1038/s41598-018-19146-y

13. Guo Y, Shi D, Zhang J, Mao S, Wang L, Zhang W, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel significant prognostic factor for patients with metastatic prostate cancer undergoing cytoreductive radical prostatectomy. *J Cancer.* (2019) 10:81–91. doi: 10.7150/jca.27210

14. Song B, Hu R, Pei L, Cao Y, Chen P, Sun S, et al. Dual antiplatelet therapy reduced stroke risk in high-risk patients with transient ischaemic attack assessed by ABCD3-I score. *Eur J Neurol.* (2019) 26:610–6. doi: 10.1111/ene.13864

15. Zhao L, Wang R, Song B, Tan S, Gao Y, Fang H, et al. Association between atherogenic dyslipidemia and recurrent stroke risk in patients with different subtypes of ischemic stroke. *Int J Stroke.* (2015) 10:752–8. doi: 10.1111/ijs.12471

16. Stroke—1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. *Stroke.* (1989) 20:1407–31. doi: 10.1161/01.STR.20.10.1407

17. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. *Clin Neurol Neurosurg.* (2009) 111:483–95. doi: 10.1016/j.clineuro.2009.04.001

18. Kim JY, Park J, Chang JY, Kim SH, Lee JE. Inflammation after ischemic stroke: the role of leukocytes and glial cells. *Exp Neurol.* (2016) 25:241–51. doi: 10.1016/j.expneurol.2016.06.049

19. Yang M, Pan Y, Li Z, Yan H, Zhao X, Liu L, et al. Platelet count predicts adverse clinical outcomes after ischemic stroke or TIA: subgroup analysis of CNSR II. *Front Neurol.* (2019) 10:370. doi: 10.3389/fneur.2019.00370

20. Kim J, Song TJ, Park JH, Lee Hs, Nam CM, Nam HS, et al. Different prognostic value of white blood cell subtypes in patients with acute cerebral infarction. *Atherosclerosis.* (2012) 222:464–7. doi: 10.1016/j.atherosclerosis.2012.02.042

21. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. *Ann Intensive Care.* (2013) 3:4. doi: 10.1186/2110-5820-3-4

22. Lam FW, Cruz MA, Leung HC, Parikh KS, Smith CW, Rumbaut RE. Histone induced platelet aggregation is inhibited by normal albumin. *Thromb Res.* (2013) 132:69–76. doi: 10.1016/j.thromres.2013.04.018

23. Dziedzic T, Skowik A, Szczudlik A. Serum albumin level as a predictor of ischemic stroke outcome. *Stroke.* (2004) 35:e156–8. doi: 10.1161/01.STR.0000126609.18735.be

24. Kimberly WT, Lima FO, O’Connor S, Furie KL. Sex differences and hemoglobin levels in relation to outcomes. *Neurology.* (2013) 80:719–24. doi: 10.1212/WNL.0b013e3182852ff

25. Sacco S, Marini C, Olivieri L, Pistoia F, Carolei A. Contribution of hematocrit to early mortality after ischemic stroke. *European neurology.* (2007) 58:233–8. doi: 10.1159/000107946

26. Barlas RS, Honney K, Loke YK, McCall SJ, Bettencourt-Silva JH, Clark AB, et al. Impact of hemoglobin levels and anemia on mortality in acute stroke: analysis of UK Regional Registry Data, Systematic Review, and Meta-Analysis. *J Am Heart Assoc.* (2016) 5:e003019. doi: 10.1161/JAHA.115.003019

27. Kellert L, Martin E, Sylker M, Bauer H, Gussmann P, Diedler J, et al. Cerebral oxygen transport failure: decreasing hemoglobin and hematocrit levels after ischemic stroke predict poor outcome and mortality: StROKE: RelevAnt Impact of hemoglobin, Hematocrit and Transfusion (STRAIGHT)–an observational study. *Stroke.* (2011) 42:2832–7. doi: 10.1161/STROKEAHA.110.606665

28. Zhang Q, Lei YX, Wang Q, Jin YF, Fu RL, Geng HH, et al. Serum albumin level is associated with the recurrence of acute ischemic stroke. *Am J Emerg Med.* (2016) 34:1812–6. doi: 10.1016/j.ajem.2016.06.049

29. Chang JY, Lee JS, Kim BJ, Kim JT, Lee J, Cha JK, et al. Influence of hemoglobin concentration on stroke recurrence and composite vascular events. *Stroke.* (2020) 51:1309–12. doi: 10.1161/STROKEAHA.119.028058

30. Peng D, Zhang CJ, Tang Q, Zhang L, Yang KW, Yu XT, et al. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy. *BMC Urol.* (2018) 18:20. doi: 10.1186/s12894-018-0333-8

31. Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurfluh S, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. *Am J Med.* (2019) 133:713–22.e7. doi: 10.1016/j.amjmed.2019.10.031

32. Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. *Nat Rev Neurol.* (2015) 11:524–35. doi: 10.1038/nrneurol.2015.144

33. Martineau J, Bauer JD, Isenring E, Cohen S. Malnutrition determined by the patient-generated subjective global assessment is associated with poor outcomes in acute stroke patients. *Clin Nutr.* (2005) 24:1073–7. doi: 10.1016/j.clnu.2005.08.010

34. Mengke T, Youfeng L, Xiao W, Xuan T, Lu-lu P, Xin W, et al. Hemoglobin, albumin, lymphocyte, and platelet score is associated with adverse clinical outcomes of acute ischemic stroke: a prospective cohort study. *Res Square.* (2020). doi: 10.21203/rs.3.rs-38304/v1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Tian, Li, Wang, Tian, Pei, Wang, Zhang, Sun, Wu, Sun, Ning, Buonanno, Xu and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.